Oakland, CA, United States of America

Eliane Trepagnier

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Oakland, CA (US) (2022)
  • Fremont, CA (US) (2022)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):

Title: Eliane Trepagnier: Innovator in Sequencing Technologies

Introduction

Eliane Trepagnier is a prominent inventor based in Oakland, CA (US). She has made significant contributions to the field of nucleic acid sequencing, holding a total of 3 patents. Her work focuses on developing advanced methods that enhance the accuracy and efficiency of sequencing technologies.

Latest Patents

Trepagnier's latest patents include innovative methods for accelerated sequencing. These methods involve generating a coupled sequencing read pair for a polynucleotide and analyzing it to detect variants, even at loci that are not directly sequenced. Additionally, she has developed analytical methods that utilize these coupled sequencing read pairs to construct or validate consensus sequences. Another notable patent outlines methods for nucleic acid detection, which enable higher sequencing accuracy, particularly for low-accuracy reads such as homopolymer sequences.

Career Highlights

Eliane Trepagnier is currently associated with Ultima Genomics, Inc., where she continues to push the boundaries of sequencing technology. Her work has been instrumental in advancing the capabilities of nucleic acid analysis, making significant strides in the field.

Collaborations

Trepagnier collaborates with notable colleagues, including Mark Pratt and Gilad Almogy, contributing to a dynamic research environment that fosters innovation.

Conclusion

Eliane Trepagnier's contributions to sequencing technologies exemplify her commitment to advancing scientific knowledge and improving methodologies in the field. Her innovative patents and collaborative efforts position her as a key figure in the realm of nucleic acid research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…